# Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

> **NCT03250624** · PHASE2 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 63 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** CD5024 0.3% cream
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03250624
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-01
- **Primary completion:** 2017-06-26
- **Final completion:** 2017-06-26
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2023-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03250624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03250624, "Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03250624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*